Experienced in Asymptomatic Bacteriuria

Dr. Mark W. Jalkut

Urology
Associated Urologists Of North Carolina PA
3821 Ed Dr, 
Raleigh, NC 
Accepting New Patients
Offers Telehealth
Experienced in Asymptomatic Bacteriuria
Associated Urologists Of North Carolina PA
3821 Ed Dr, 
Raleigh, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Mark Jalkut is an Urologist in Raleigh, North Carolina. Dr. Jalkut is rated as an Experienced provider by MediFind in the treatment of Asymptomatic Bacteriuria. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Muscle Invasive Bladder Cancer, Ureteroscopy, and Reconstructive Urology Surgery. Dr. Jalkut is currently accepting new patients.

His clinical research consists of co-authoring 7 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Urology
Licenses
Urology in NC
Hospital Affiliations
Johnston Health
Rex Hospital
Languages Spoken
English
Slovak
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Essence Healthcare
  • INSURANCE PLAN
  • MEDICARE MAPD
FirstCarolinaCare
  • HMO
  • MEDICARE MAPD
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
TeamCare
  • OTHER COMMERCIAL
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

ASSOCIATED UROLOGISTS OF NORTH CAROLINA PA
3821 Ed Dr, Raleigh, NC 27612

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer
QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 14, 2025
Intervention Type: Drug
Study Drugs: ALT-803, Bacillus Calumette-Guerin
Study Phase: Phase 2/Phase 3
A Prospective, Multicenter, Double Blind, Randomized, Clinical Study to Evaluate the Safety and Efficacy of the Optilume™ BPH Catheter System in Men With Symptomatic BPH
A Prospective, Multicenter, Double Blind, Randomized, Clinical Study to Evaluate the Safety and Efficacy of the Optilume™ BPH Catheter System in Men With Symptomatic BPH
Enrollment Status: Active_not_recruiting
Publish Date: April 09, 2025
Intervention Type: Device
Study Phase: Not Applicable
VERACITY - Randomized, Active-Controlled, Phase 3 Study of VERU-111 for the Treatment of Metastatic Castration-Resistant Prostate Cancer in Patients Who Have Failed Prior Treatment With at Least One Androgen Receptor Targeting Agent
VERACITY - Randomized, Active-Controlled, Phase 3 Study of VERU-111 for the Treatment of Metastatic Castration-Resistant Prostate Cancer in Patients Who Have Failed Prior Treatment With at Least One Androgen Receptor Targeting Agent
Enrollment Status: Terminated
Publish Date: February 05, 2024
Intervention Type: Drug
Study Drugs: VERU-111, Enzalutamide, Abiraterone, Darolutamide and Apalutamide
Study Phase: Phase 3
A Post-Market Evaluation of the Altis® Single Incision Sling System Versus Transobturator or Retropubic Mesh Sling in the Treatment of Female Stress Urinary Incontinence
A Post-Market Evaluation of the Altis® Single Incision Sling System Versus Transobturator or Retropubic Mesh Sling in the Treatment of Female Stress Urinary Incontinence
Enrollment Status: Completed
Publish Date: December 04, 2023
Intervention Type: Device
A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, Double-Dummy Study in Adolescent and Adult Female Participants Comparing the Efficacy and Safety of Gepotidacin to Nitrofurantoin in the Treatment of Uncomplicated Urinary Tract Infection (Acute Cystitis)
A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, Double-Dummy Study in Adolescent and Adult Female Participants Comparing the Efficacy and Safety of Gepotidacin to Nitrofurantoin in the Treatment of Uncomplicated Urinary Tract Infection (Acute Cystitis)
Enrollment Status: Completed
Publish Date: July 18, 2023
Intervention Type: Drug
Study Drugs: Gepotidacin, Nitrofurantoin
Study Phase: Phase 3
Open-Label, Proof-of-Concept and Dose Finding Phase 1b/2 Study of VERU-100 in Men With Advanced Prostate Cancer
Open-Label, Proof-of-Concept and Dose Finding Phase 1b/2 Study of VERU-100 in Men With Advanced Prostate Cancer
Enrollment Status: Terminated
Publish Date: May 19, 2023
Intervention Type: Drug
Study Drug: VERU-100
Study Phase: Phase 1/Phase 2
Phase 1-2a Safety, Tolerability, and Pharmacodynamics Controlled Study of NOV-001 in Healthy Volunteers and Patients With Enteric Hyperoxaluria
Phase 1-2a Safety, Tolerability, and Pharmacodynamics Controlled Study of NOV-001 in Healthy Volunteers and Patients With Enteric Hyperoxaluria
Enrollment Status: Terminated
Publish Date: May 17, 2023
Intervention Type: Drug, Biological, Combination product
Study Phase: Phase 1/Phase 2
Long-Term Prospective Registry to Evaluate Treatment Decisions and Clinical Outcomes in Patients With Favorable Intermediate-Risk Localized Prostate Cancer Following Cell Cycle Progression (CCP) Testing (Prolaris® Test)
Long-Term Prospective Registry to Evaluate Treatment Decisions and Clinical Outcomes in Patients With Favorable Intermediate-Risk Localized Prostate Cancer Following Cell Cycle Progression (CCP) Testing (Prolaris® Test)
Enrollment Status: Terminated
Publish Date: June 23, 2022
Intervention Type: Diagnostic test
An Evaluation of the Vesair® Bladder Control System for the Treatment of Stress Urinary Incontinence in Post-Menopausal Women
An Evaluation of the Vesair® Bladder Control System for the Treatment of Stress Urinary Incontinence in Post-Menopausal Women
Enrollment Status: Terminated
Publish Date: May 13, 2022
Intervention Type: Other, Device
Study Phase: Not Applicable
A Registry for Hereditary Cancer Risk Assessment and Genetic Testing Among Men With Prostate Cancer in the Community Urology Practice Setting
A Registry for Hereditary Cancer Risk Assessment and Genetic Testing Among Men With Prostate Cancer in the Community Urology Practice Setting
Enrollment Status: Completed
Publish Date: November 05, 2020
View 9 Less Clinical Trials

7 Total Publications

Prolonged Progression-Free Survival, Disease-Free Survival and Cystectomy Avoidance with IL-15 Receptor Lymphocyte-Stimulating Agent NAI plus BCG in BCG-Unresponsive Papillary-Only NMIBC.
Prolonged Progression-Free Survival, Disease-Free Survival and Cystectomy Avoidance with IL-15 Receptor Lymphocyte-Stimulating Agent NAI plus BCG in BCG-Unresponsive Papillary-Only NMIBC.
Journal: The Journal of urology
Published: September 16, 2025
Similar Doctors
Advanced in Asymptomatic Bacteriuria
Dr. Scott D. Baker
Urology
Advanced in Asymptomatic Bacteriuria
Dr. Scott D. Baker
Urology

Associated Urologists Of North Carolina PA

3821 Ed Dr, 
Raleigh, NC 
 (0.1 miles away)
919-758-8677
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Scott Baker is an Urologist in Raleigh, North Carolina. Dr. Baker is rated as an Advanced provider by MediFind in the treatment of Asymptomatic Bacteriuria. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Asymptomatic Bacteriuria, Ureteroscopy, and Ureteral Reconstruction. Dr. Baker is currently accepting new patients.

Advanced in Asymptomatic Bacteriuria
Dr. Brian C. Bennett
Urology
Advanced in Asymptomatic Bacteriuria
Dr. Brian C. Bennett
Urology

Associated Urologists Of North Carolina PA

3821 Ed Dr, 
Raleigh, NC 
 (0.1 miles away)
919-758-8677
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Brian Bennett is an Urologist in Raleigh, North Carolina. Dr. Bennett is rated as a Distinguished provider by MediFind in the treatment of Asymptomatic Bacteriuria. His top areas of expertise are Enlarged Prostate (BPH), Familial Prostate Cancer, Prostate Cancer, Ureteroscopy, and Bladder Reconstruction. Dr. Bennett is currently accepting new patients.

Advanced in Asymptomatic Bacteriuria
Dr. Jay Han Kim
Urology
Advanced in Asymptomatic Bacteriuria
Dr. Jay Han Kim
Urology

Triangle Urology Associates

205 Frasier Street, 
Durham, NC 
 (19.1 miles away)
919-470-4000
Experience:
33+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jay Han Kim is an Urologist in Durham, North Carolina. Dr. Han Kim has been practicing medicine for over 33 years and is rated as an Advanced provider by MediFind in the treatment of Asymptomatic Bacteriuria. His top areas of expertise are Enlarged Prostate (BPH), Asymptomatic Bacteriuria, Urinary Incontinence, Ureteroscopy, and Prostatectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Jalkut's expertise for a condition
ConditionClose
    View All 32 Advanced Conditions
    View All 23 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile